Viusid Pets: Veterinary Product Profile

Viusid Pets is a named branded product for Dogs and cats; manufacturer positioning is kept separate from independent clinical and regulatory evidence.

oral liquid complementary feed in 30 mL and 150 mL presentations. Intended species: Dogs and cats.

The official composition per 100 mL lists glucosamine obtained by fermentation and maltodextrin, with DL-malic acid, sodium propionate, potassium sorbate corresponding to 0.15 g sorbic acid, zinc sulphate monohydrate 0.015 g, L-arginine, ascorbic acid, calcium D-pantothenate, pyridoxine hydrochloride, folic acid, cyanocobalamin or vitamin B12, glycine, ammoniated glycyrrhizic acid, and flavourings. The actual package should be checked for country-specific quantitative details.

Catalysis markets Viusid Pets as nutritional and antioxidant support for dogs and cats, including support for appetite, vitality, immune function, and recovery. The current manufacturer pet page does not establish a cancer-treatment indication. A competitor table or retailer oncology category must not convert this complementary feed into an antineoplastic product.

May be discussed only as supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive objective, baseline, review date, adverse-event plan, and stopping rule with the veterinarian.

Bring the current label, lot, full ingredient panel, country version, complete diet, medicines, and supplements to the treating veterinarian.

The manufacturer page supports identity, species, presentation, and composition. The May 2026 Colombian ICA list identifies VIUSID PETS as supplemental animal feed under registration 17566SL. Neither source supplies a controlled canine or feline oncology trial of the finished product. Ingredient mechanisms and general nutritional evidence do not establish tumour response or survival.

Review total zinc and vitamin exposure, glycyrrhizic-acid or liquorice-related concerns, blood pressure, potassium balance, heart or kidney disease, diabetes, gastrointestinal tolerance, pregnancy, and concurrent medicines. Preservatives and flavourings may matter to individual animals. Country formulas can differ, so the current label should be reconciled with every diet and supplement.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

Catalysis describes Viusid Pets as complementary feed. Colombia ICA's May 2026 official register lists it as supplemental feed under 17566SL. That feed registration does not constitute approval as a veterinary cancer medicine in Colombia, Spain, the EU, or another market.

Spain; European Union; Colombia

Record the 30 mL or 150 mL version, country, lot, label, diet, medicines, and supportive goal. Track appetite, vomiting, diarrhoea, stool, drinking, urination, energy, weight, swelling, blood pressure or electrolytes when clinically relevant, and treatment adherence. Oncology measurements remain determined by diagnosis and treatment rather than supplement use.